A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
Summary
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with Neurodegenerative Disorders.
Timeline
- Start
- 2021-06-28
- Primary completion
- 2022-07-04
- Completion
- 2022-08-31
Outcome
Met primary endpoint
registry analysis (other test); PD - Placebo vs PD - Active; p = 0.0479; Least Squares Mean 5.4822 (95% CI 0.0575 to 10.9069); Mixed Models Analysis NCT04739423 ↗
registry analysis (other test); PD - Placebo vs PD - Active; p = 0.0161; Least Squares Mean 4.7954 (95% CI 0.9843 to 8.6064); Mixed Models Analysis NCT04739423 ↗
registry analysis (other test); PD - Placebo vs PD - Active; p = 0.0237; Least Squares Mean 167.29 (95% CI 25.36 to 309.23); Mixed Models Analysis NCT04739423 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clenbuterol | Small molecule | — | — |
| Subject | Nadolol | Unknown | — | — |